Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Strontium Radioisotopes”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1990

Ion exchange chromatography on a new form of tin dioxide for the isolation of strontium radioisotopes from fission products: an application to milk samples.

An amorphous, partially-reduced tin dioxide, having properties of an inorganic exchanger, was tested for application to fission product separations. Due to the good sorption of both strontium and barium the application of the exchanger to radiostrontium isolation from fission product mixtures is subject to important restrictions. An application to 90Sr determination in milk is proposed.

Animals↗
PubMed2002

Strontium-89: a novel treatment for a case of osteosclerotic myeloma associated with life-threatening neuropathy.

Osteosclerotic myeloma is a rare disorder characterized by paraproteinaemia and osteosclerosis, and may be associated with a progressive peripheral neuropathy. Patients with widespread osteosclerotic lesions can succumb from neurological complications despite systemic chemotherapy. We present a case of disseminated osteosclerotic myeloma associated with POEMS (peripheral neuropathy, organomegaly, endocrinopathy, M band, skin changes) syndrome, which was complicated by a rapidly progressive, life-threatening neuropathy. The patient's symptoms remained unchanged in the face of combination chemotherapy. However, a substantial improvement was seen following outpatient treatment with the commonly available radioisotope strontium 89 in combination with steroids.

Anti-Inflammatory Agents↗
PubMed1994

Systemic administration of new therapeutic radioisotopes, including phosphorus, strontium, samarium, and rhenium.

New advances in systemic radionuclide therapy have increased the number of treatment options available for patients with painful osseous metastases. This form of therapy has three major appeals: 1) it addresses all sites of involvement; 2) selective absorption into bone limits irradiation of normal tissues; and 3) as a result, toxicity may be reduced and the therapeutic ratio improved. The clinical experience with radioactive phosphorus, strontium, samarium, and rhenium are reviewed. To date, the best studied and the only Food and Drug Administration approved agent is strontium-89. About 60% to 90% of patients treated with strontium-89 respond with complete or partial relief of pain for a median duration of 6 months. Large, prospectively randomized clinical trials have established the efficacy of strontium-89 as a first-line therapy and as an adjuvant to external-beam radiotherapy. Particularly advantageous is its usefulness in situations in which external-beam radiotherapy options have been exhausted and normal tissue tolerance has been reached. Newer radiopharmaceuticals are still under investigation.

Bone Neoplasms↗